Analysts expect that Biodesix, Inc. (NASDAQ:BDSX – Get Rating) will post $8.60 million in sales for the current quarter, according to Zacks. Three analysts have provided estimates for Biodesix’s earnings, with the lowest sales estimate coming in at $8.11 million and the highest estimate coming in at $8.90 million. Biodesix reported sales of $11.89 million in the same quarter last year, which would suggest a negative year over year growth rate of 27.7%. The company is scheduled to issue its next quarterly earnings results on Monday, January 1st.
According to Zacks, analysts expect that Biodesix will report full year sales of $38.31 million for the current financial year, with estimates ranging from $38.00 million to $38.60 million. For the next year, analysts forecast that the business will post sales of $51.27 million, with estimates ranging from $50.50 million to $52.02 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that follow Biodesix.
Biodesix (NASDAQ:BDSX – Get Rating) last announced its quarterly earnings data on Wednesday, May 11th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.12). During the same quarter last year, the company earned ($0.23) EPS.
Shares of Biodesix stock opened at $1.61 on Friday. Biodesix has a twelve month low of $1.31 and a twelve month high of $16.40. The stock has a market cap of $64.06 million, a price-to-earnings ratio of -0.89 and a beta of 1.50. The company’s fifty day moving average is $1.79 and its 200 day moving average is $3.70.
In other news, Director Matthew Strobeck bought 558,659 shares of the stock in a transaction on Thursday, April 7th. The shares were acquired at an average cost of $1.79 per share, for a total transaction of $999,999.61. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Chairman John Patience bought 279,329 shares of the stock in a transaction on Thursday, April 7th. The stock was purchased at an average price of $1.79 per share, for a total transaction of $499,998.91. Following the completion of the purchase, the chairman now directly owns 337,926 shares in the company, valued at $604,887.54. The disclosure for this purchase can be found here. Insiders have sold a total of 20,146 shares of company stock worth $36,867 over the last 90 days. 49.80% of the stock is currently owned by corporate insiders.
Several institutional investors have recently bought and sold shares of BDSX. Morgan Stanley raised its position in shares of Biodesix by 363.2% during the 2nd quarter. Morgan Stanley now owns 43,604 shares of the company’s stock valued at $575,000 after buying an additional 34,190 shares in the last quarter. Citadel Advisors LLC raised its position in shares of Biodesix by 20.1% during the 2nd quarter. Citadel Advisors LLC now owns 54,118 shares of the company’s stock valued at $715,000 after buying an additional 9,069 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Biodesix by 3.5% during the 3rd quarter. Geode Capital Management LLC now owns 151,023 shares of the company’s stock valued at $1,241,000 after buying an additional 5,064 shares in the last quarter. Trexquant Investment LP raised its position in shares of Biodesix by 58.8% during the 3rd quarter. Trexquant Investment LP now owns 18,857 shares of the company’s stock valued at $155,000 after buying an additional 6,983 shares in the last quarter. Finally, Two Sigma Investments LP purchased a new stake in shares of Biodesix during the 3rd quarter valued at $321,000. Hedge funds and other institutional investors own 85.26% of the company’s stock.
Biodesix Company Profile (Get Rating)
Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.
- Get a free copy of the StockNews.com research report on Biodesix (BDSX)
- Lowe’s Companies Has Not Bottomed
- Silicon Labs Stock is Falling to a Better Place
- The Institutional Tide Has Turned For Cisco Systems
- Don’t Bet On Cheaper Oil, Not Yet Anway
- A Reversal In The S&P 500 Is Confirmed
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Biodesix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodesix and related companies with MarketBeat.com's FREE daily email newsletter.